Barclays PLC Verrica Pharmaceuticals Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Barclays PLC holds 31,341 shares of VRCA stock, worth $249,160. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,341

Previous 31,341 -0.0%

Holding current value

$249,160

Previous $45,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$7.95 - $7.95 $199,783 - $199,783	25,130 Added 404.6%	31,341 $45,000
Q2 2024 Aug 14, 2024	SELL	$5.89 - $9.56 $49,375 - $80,141	-8,383 Reduced 57.44%	6,211 $45,000
Q1 2024 May 15, 2024	SELL	$4.74 - $6.81 $66,578 - $95,653	-14,046 Reduced 49.04%	14,594 $86,000
Q4 2023 Feb 15, 2024	BUY	$2.93 - $7.32 $73,273 - $183,058	25,008 Added 688.55%	28,640 $210,000
Q3 2023 Nov 07, 2023	SELL	$3.75 - $7.46 $2,025 - $4,028	-540 Reduced 12.94%	3,632 $14,000
Q2 2023 Aug 03, 2023	SELL	$5.32 - $6.79 $67,830 - $86,572	-12,750 Reduced 75.35%	4,172 $24,000
Q1 2023 May 04, 2023	BUY	$2.88 - $8.51 $48,735 - $144,006	16,922 New	16,922 $110,000
Q2 2022 Aug 12, 2022	SELL	$1.81 - $8.93 $3,846 - $18,976	-2,125 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$7.59 - $9.49 $104,521 - $130,686	-13,771 Reduced 86.63%	2,125 $17,000
Q4 2021 Feb 14, 2022	BUY	$9.1 - $13.36 $95,950 - $140,867	10,544 Added 197.01%	15,896 $146,000
Q3 2021 Nov 09, 2021	BUY	$9.55 - $13.96 $34,809 - $50,884	3,645 Added 213.53%	5,352 $67,000
Q2 2021 Aug 13, 2021	SELL	$9.77 - $15.33 $84,920 - $133,248	-8,692 Reduced 83.58%	1,707 $20,000
Q1 2021 May 13, 2021	BUY	$10.51 - $17.46 $67,095 - $111,464	6,384 Added 159.0%	10,399 $157,000
Q4 2020 Feb 11, 2021	SELL	$7.41 - $12.63 $12,982 - $22,127	-1,752 Reduced 30.38%	4,015 $46,000
Q3 2020 Nov 12, 2020	SELL	$6.16 - $10.3 $6,991 - $11,690	-1,135 Reduced 16.44%	5,767 $44,000
Q2 2020 Aug 12, 2020	BUY	$9.02 - $15.12 $23,704 - $39,735	2,628 Added 61.49%	6,902 $76,000
Q1 2020 May 13, 2020	SELL	$7.14 - $16.86 $61,553 - $145,350	-8,621 Reduced 66.86%	4,274 $46,000
Q4 2019 Feb 10, 2020	BUY	$13.08 - $17.43 $85,530 - $113,974	6,539 Added 102.88%	12,895 $205,000
Q3 2019 Nov 14, 2019	SELL	$8.65 - $14.81 $16,893 - $28,923	-1,953 Reduced 23.5%	6,356 $94,000
Q2 2019 Aug 14, 2019	BUY	$7.1 - $11.62 $26,561 - $43,470	3,741 Added 81.9%	8,309 $97,000
Q1 2019 May 15, 2019	BUY	$7.95 - $14.07 $36,315 - $64,271	4,568 New	4,568 $50,000
Q4 2018 Feb 14, 2019	SELL	$6.75 - $16.12 $14,667 - $35,028	-2,173 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$13.94 - $19.88 $30,291 - $43,199	2,173 New	2,173 $35,000

Others Institutions Holding VRCA

# of Institutions

Shares Held

14.2M

Call Options Held

9.9K

Put Options Held

6.5K

View Full List

About Verrica Pharmaceuticals Inc.

Ticker VRCA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,094,100
Market Cap $327M
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...

More about VRCA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account